Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine maintenance after oxaliplatin-based first-line chemotherapy in advanced colorectal cancer
ChiCTR-TRC-13003504Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colorectal adenocarcinoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Started Mar 2013; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-TRC-13003504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003504.